Several other ongoing pan-cancer trials are investigating NRG1-targeted therapies, including afatinib (NCT04410653) and seribantumab (NCT04383210), an anti-HER3 monoclonal antibody demonstrating significant anti-tumor activity in patients with NRG1 fusion-positive, ERBB-targeted therapy-naïve tumors in the phase II CRESTONE study. Here, NRG1 is linked to cancer.